Allan Coukell is Pew’s senior director for health programs. He oversees initiatives related to drug and medical device innovation and safety, medical conflicts-of-interest, the pharmaceutical supply chain, pharmacy compounding, antibiotic resistance, prescription drug abuse, FDA and specialty drugs, food safety, school nutrition, as well as other efforts related to health costs and care delivery.
Prior to joining Pew, he practiced as a clinical pharmacist in oncology at the London Health Sciences Center and Ontario Regional Cancer Center, served as a senior medical writer and editor with the medical journal publisher Adis International, and covered health and science as a reporter and producer for WBUR (NPR) in Boston and Radio New Zealand. He is Vice Chair of the Medical Device Innovation Consortium and a board member of the Reagan Udall Foundation for the FDA. He served previously as consumer representative on the FDA’s Cardiovascular and Renal Drugs Advisory Committee.
On Monday, January 12, The Pew Charitable Trusts submitted a letter to the Medicare Payment Advisory Commission (MedPAC) encouraging the organization to recommend that Congress allow patient review and restriction (PRR) programs in Medicare Part D. PRR programs are a tool already utilized in some commercial insurance plans as well as state Medicaid programs to support the safe and appropriate use... Read More
On December 5, The Pew Charitable Trusts wrote a letter to Ways and Means Health Subcommittee Chairman Kevin Brady and Ranking Member Jim McDermott supporting language in the Protecting the Integrity of Medicare Act of 2014 that will allow Medicare Part D plan sponsors to use drug management programs for patients at risk of prescription drug abuse. Read More